Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Organisation › Details

Akarna Therapeutics Ltd.

Akarna Therapeutics is a privately held biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment. Akarna’s lead program is a potential best-in-class FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH). Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies. Akarna is a UK-registered company with offices in Cambridge, UK and San Diego, USA. *


Period Start 2016-02-16 existent
Products Industry FXR agonist
  Industry 2 drug development
Person Person Mohan, Raju (Escalier Biosciences 201803 CEO before CEO of Akarna Therapeutics)
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street Cowley Road
  City CB4 0WS Cambridge, Cambridgeshire
    Address record changed: 2016-02-29
Basic data Employees n. a.
    * Document for �About Section�: Akarna Therapeutics Ltd.. (2/16/16). "Press Release: Akarna Therapeutics Raises $15 Million Series B Financing to Develop Novel FXR Agonist-Based Therapies for the Treatment of NASH and other Fibrotic Diseases". San Diego, CA & Cambridge.
Record changed: 2017-04-01


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Akarna Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top